Originally developed by US biopharma company Esperion, Nilemdo was approved by the European Medicines Agency (EMA) in April, a couple of months after it got a green light from the US FDA as Nexletol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback